XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Share-based Compensation (Tables)
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Summary of Assumptions of Fair Value of Option Pricing Granted The fair value of the stock options granted during the three months ended September 30, 2021 was determined using the Black-Scholes option pricing model with the following assumptions:

 

 

 

THREE MONTHS ENDED
SEPTEMBER 30,

 

 

 

2021

 

Expected volatility

 

87.76% - 87.87%

 

Expected term (years)

 

5.50 - 6.08

 

Risk free interest rate

 

0.79% - 0.97%

 

Expected dividend yield

 

 

 

Exercise price

 

12.80 -13.00

 

Summary of Nonvested Restricted Common Stock A summary of the status of our nonvested restricted common stock at September 30, 2021 and changes during the nine months ended September 30, 2021 is as follows:

 

 

 

 

Restricted Shares

 

Nonvested restricted stock at December 31, 2020

 

 

1,184,252

 

Shares granted

 

 

1,589,622

 

Shares vested

 

 

(365,520

)

Outstanding nonvested restricted stock at September 30, 2021

 

 

2,408,354

 

 

Summary of Equity-based Compensation

Share-based compensation is classified in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2021 and 2020 as follows:

 

 

 

 

THREE MONTHS ENDED
SEPTEMBER 30,

 

 

NINE MONTHS ENDED
SEPTEMBER 30,

 

(in thousands)

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Research and development

 

$

266

 

 

$

47

 

 

$

620

 

 

$

107

 

General and administrative

 

 

789

 

 

 

228

 

 

 

1,496

 

 

 

368

 

 

 

$

1,055

 

 

$

275

 

 

$

2,116

 

 

$

475

 

Restricted Shares  
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]  
Summary of Assumptions of Fair Value of Restricted Common Shares Pricing Granted The assumptions that went into the option pricing models for determining the fair value of Rallybio Holdings incentive units granted during the nine months ended September 30, 2021 and 2020, prior to the Liquidation of Rallybio Holdings are as follows and do not include the retrospective adjustments described in Note 2:

 

 

 

 

NINE MONTHS ENDED
SEPTEMBER 30,

 

 

 

2021

 

 

2020

 

Expected volatility

 

71.7% - 99.5%

 

 

 

95.0

%

Expected term (years)

 

0.58 - 1.00

 

 

 

1.50

 

Risk free interest rate

 

0.04% - 0.10%

 

 

 

0.16

%

Expected dividend yield